MORÁŇ, Lukáš, Barbora VAVRUŠÁKOVÁ, Kateřina VAŠÍČKOVÁ, Lenka KREJČÍ, Kamila SOUČKOVÁ, Táňa MACHÁČKOVÁ, Ondřej SLABÝ and Marek SVOBODA. Role of Endoplasmic Reticulum Stress in Immune Surveillance and Immunotherapy of Ovarian and Renal Cell Carcinoma. In Imaging Principles of Life. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Role of Endoplasmic Reticulum Stress in Immune Surveillance and Immunotherapy of Ovarian and Renal Cell Carcinoma
Authors MORÁŇ, Lukáš (203 Czech Republic, belonging to the institution), Barbora VAVRUŠÁKOVÁ (203 Czech Republic, belonging to the institution), Kateřina VAŠÍČKOVÁ (203 Czech Republic, belonging to the institution), Lenka KREJČÍ (203 Czech Republic, belonging to the institution), Kamila SOUČKOVÁ (203 Czech Republic, belonging to the institution), Táňa MACHÁČKOVÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Marek SVOBODA (203 Czech Republic, belonging to the institution).
Edition Imaging Principles of Life, 2023.
Other information
Original language English
Type of outcome Presentations at conferences
Field of Study 30204 Oncology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/23:00134719
Organization unit Faculty of Medicine
Keywords in English Ovarian Cell Carcinoma; Renal Cell Carcinoma; Endoplasmic Reticulum Stress; Immune Surveillance
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 29/4/2024 09:17.
Abstract
Role of Endoplasmic Reticulum Stress in Immune Surveillance and Immunotherapy of Ovarian and Renal Cell Carcinoma - conference abstract.
Links
NU21-03-00539, research and development projectName: Vliv stresu endoplazmatického retikula na imunitní stav nádorů a účinnost imunoterapie při léčbě ovariálního a renálního karcinomu
Investor: Ministry of Health of the CR, The effect of endoplasmic reticulum stress on the immune status of tumors and the efficiency of immunotherapy in the treatment of ovarian and renal cell carcinoma, Subprogram 1 - standard
PrintDisplayed: 26/8/2024 19:10